C01CA17 midodrine
CARDIOVASCULAR SYSTEM ›CARDIAC THERAPY ›CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES ›Adrenergic and dopaminergic agents
健保收載品項 TFDA 在效許可證 5 FDA 已核准
台灣藥品與外觀
健保收載品名："培力" 邁妥林錠、脈索林錠2.5毫克、高特隆錠
無外觀照
鹽酸米多君
無外觀照
邁妥林鹽酸鹽
資料來源：食藥署「西藥許可證」＋「藥品 ATC 碼」＋「藥品外觀」＋「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。
適應症
台灣 TFDA 核准適應症
- 體質性血壓過低、直立性循環系統失統、病後、手術後及產後脂血壓過低。
- 體質性血壓過低、直立性循環系統失調、病後、手術後及產後之血壓過低。
- 降血壓劑。
- 降血壓藥。
美國 FDA 適應症（英文原文對照）
INDICATIONS AND USAGE Midodrine hydrochloride tablets, USP are indicated for the treatment of symptomatic orthostatic hypotension (OH). Because midodrine hydrochloride tablets, USP can cause marked elevation of supine blood pressure (BP > 200 mmHg systolic), it should be used in patients whose lives are considerably impaired despite standard clinical care, including non-pharmacologic treatment (such as support stockings), fluid expansion, and lifestyle alterations. The indication is based on midodrine hydrochloride tablets, USP effect on increases in 1-minute standing systolic blood pressure, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of midodrine hydrochloride tablets, USP principally improved ability to perform life activities, have not been established. Further clinical trials are underway to verify and describe the clinical benefits of midodrine hydrochloride tablets, USP. After initiation of treatment, midodrine hydrochloride tablets, USP should be continued only for patients who report significant symptomatic improvement.
資料來源：食藥署西藥許可證適應症（中文）、openFDA US SPL（英文，僅供對照）。
健保給付規定
查無健保特殊給付規定條款；本藥品依一般健保藥品支付規定給付。
實證補充
本藥品尚無實證補充整理（未來新增 Review／指引知識時補列）。
台灣藥品與適應症：食藥署西藥許可證＋ATC＋外觀＋仿單開放資料 · FDA：openFDA US SPL · 健保給付：健保署「全民健康保險藥品給付規定」（更新日 2026-06-09）· 實證補充：人工彙整。 本頁為資訊整理，實際給付與適應症以主管機關公告為準。